ECO 2026: tirzepatide shows potential for T1D treatment - Pharmaceutical Technology

During ECO 2026, a study was presented analysing the use of tirzepatide, a dual GIP and GLP-1 agonist, in treating type 1 diabetes (T1D). GLP-1 agonists have had a dramatic surge in popularity in recent years as a treatment for obesity and type 2 diabetes (T2D). The review study analysed six observational studies of patients with T1D using tirzepatide as an adjunct treatment to insulin therapy. Credit: KK Stock / Shutterstock.com. During the 2026 European Congress on Obesity (ECO) in Istanbul, a meta-analysis was presented analysing the use of tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1)…

Source: Pharmaceutical Technology